Studies of interest involve various anti-cancer agents, including agents such as poly (ADP-ribose) polymerase inhibitors (PARPi), radioligand therapy with 177Lu-PSMA-617, immunotherapy, oral ADT, as well as a combination of these treatments, in addition to using effective drugs in earlier disease phases such as mCNPC and nmCNPC. Here, FOLH1 is linked to cancer.